Investment case
NRx Pharmaceuticals, Inc.
NRXP · 2 developments mapped · last assessed 2026-09-16
Market Ontology has mapped 2 macro, policy, and market developments to NRx Pharmaceuticals, Inc. since 2026-08-17. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for NRXP yet, so no modelled value is shown. The NRXP valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run NRXP on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
NRx Pharmaceuticals Reports FDA Reclassification of Ketamine Amendment to Minor Amendment
Direct regulatory progress for a key product candidate, reducing approval timeline uncertainty.
· Moves probability of approval (poa), time to market, discount rate (due to reduced risk)
- Open question
NRx Pharmaceuticals, Inc. Follow-On — $22M
Direct dilution from increased share count; improved liquidity and balance sheet strength for operations and R&D.
· Moves shares outstanding, cash runway, probability of successful r&d
What changed, by assumption
- 2026-09-16NRx Pharmaceuticals Reports FDA Reclassification of Ketamine Amendment to Minor Amendment
- 2026-08-17NRx Pharmaceuticals, Inc. Follow-On — $22M
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-17 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-17 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-16 | NRx Pharmaceuticals Reports FDA Reclassification of Ketamine Amendment to Minor Amendment | Bullish | 1-3m | 0.80 |
| 2026-08-17 | NRx Pharmaceuticals, Inc. Follow-On — $22M | mixed | 1-3m | 0.80 |